biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > another perspective on the recent Cresence transaction

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Jul 05, 2022 8:30pm

165 Views

Post# 34803772

RE:another perspective on the recent Cresence transaction

I agree with Prescient Reports take on Cresence. The deal was announced with a very poor press release but the news was great.

Disclaimer:
I was asked to be a partner in Prescient Reports almost three years ago. I turned it down for good reasons. I'm sure there are readers here who know who the "good friend" is who has lots of shares. The opinions in this piece should be quite well informed.

jd

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec